STAT October 21, 2024
The company says it wants to correct ‘inaccuracies’ as some urge the FTC to block the deal
Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s parent — will not raise competitive concerns or diminish its ability to provide services to other drug companies.
...